ERBB2 and breast carcinoma: 17.9% of patients received further chemotherapy in the adjuvant setting (n = 80); among HER2-positive breast cancer patients, more than 90% received adjuvant anti-HER2 therapy (n = 177); 227 patients received adjuvant hormonal therapy.